Schering-Plough, Merck narrow cholesterol-drug review

Published on .

Schering-Plough Corp. and Merck & Co. narrowed the agency review for their co-marketed cholesterol-lowering drug to two shops. DDB Worldwide and Grey Worldwide, both New York, are believed to be the finalists, according to executives close to the situation. Y&R Advertising, New York, was cut from the process. The product, known by the generic name ezetimibe, is expected to hit the market in two years.

Copyright December 2000, Crain Communications Inc.

Most Popular
In this article: